Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial

References

• de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70. doi:10.1002/ijc.30716.
   PubMed Web of Science ®Google Scholar
• de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–e190. doi:10.1016/S2214-109X(19)30488-7.
   PubMed Web of Science ®Google Scholar
• Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Vietnam. Summary Report. 2019 [accessed 2020 Jun 30]. https://hpvcentre.net/statistics/reports/VNM.pdf .
   Google Scholar
• Bergman H, Buckley BS, Villanueva G, Petkovic J, Garritty C, Lutje V, Riveros-Balta AX, Low N, Henschke N. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related disease in females and males. Cochrane Database Syst Rev. 2019;2019(11):CD013479. doi:10.1002/14651858.CD013479.
   Web of Science ®Google Scholar
• Luxembourg A, Moeller E. 9-valent human papillomavirus vaccine: a review of the clinical development program. Expert Rev Vaccines. 2017;16(11):1119–39. doi:10.1080/14760584.2017.1383158.
   PubMed Web of Science ®Google Scholar
• Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1997–2008. doi:10.1158/1055-9965.EPI-14-0410.
   PubMed Web of Science ®Google Scholar
• Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, Bosch F, de Sanjosé S. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7(1):38. doi:10.1186/1750-9378-7-38.
   PubMed Web of Science ®Google Scholar
• de Sanjosé S, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, Joura EA, Maldonado P, Laco J, Bravo IG, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013;49(16):3450–61. doi:10.1016/j.ejca.2013.06.033.
   PubMed Web of Science ®Google Scholar
• Alemany L, Saunier M, Tinoco L, Quirós B, Alvarado-Cabrero I, Alejo M, Joura EA, Maldonado P, Klaustermeier J, Salmerón J, et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: A worldwide study in 597 samples. Eur J Cancer. 2014;50(16):2846–54. doi:10.1016/j.ejca.2014.07.018.
   PubMed Web of Science ®Google Scholar
• Alemany L, Saunier M, Alvarado-Cabrero I, Quirós B, Salmeron J, Shin H-R, Pirog EC, Guimerà N, Hernandez-Suarez G, Felix A, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015;136(1):98–107. doi:10.1002/ijc.28963.
   PubMed Web of Science ®Google Scholar
• Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt R, Joura E. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805–14. doi:10.1086/597071.
   PubMed Web of Science ®Google Scholar
• Serrano B, de Sanjosé S, Tous S, Quiros B, Muñoz N, Bosch X, Alemany L. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer. 2015;51(13):1732–41. doi:10.1016/j.ejca.2015.06.001.
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23. doi:10.1056/NEJMoa1405044.
   PubMed Web of Science ®Google Scholar
• Huh WK, Joura EA, Giuliano AR, Iversen O-E, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143–59. doi:10.1016/S0140-6736(17)31821-4.
   PubMed Web of Science ®Google Scholar
• Castellsague X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, Group T, Shields C, Liu K, Maansson R, et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33(48):6892–901. doi:10.1016/j.vaccine.2015.06.088.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, Huang L-M, Kim DS, Pitisuttithum P, Chen J, et al. Immunogenicity and safety of a 9-valent HPV vaccine. Pediatrics. 2015;136(1):e28–39. doi:10.1542/peds.2014-3745.
   PubMed Web of Science ®Google Scholar
• Baloch Z, Li Y, Yuan T, Feng Y, Liu Y, Tai W, Liu L, Wang B, Zhang A-M, Wu X, et al. Epidemiologic characterization of human papillomavirus (HPV) infection in various regions of Yunnan Province of China. BMC Infect Dis. 2016;16(1):228. doi:10.1186/s12879-016-1562-7.
   PubMed Web of Science ®Google Scholar
• Azuma Y, Kusumoto-Matsuo R, Takeuchi F, Uenoyama A, Kondo K, Tsunoda H, Nagasaka K, Kawana K, Morisada T, Iwata T, et al. Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2/3 and invasive cervical cancer in Japanese women. Jpn J Clin Oncol. 2014;44(10):910–17. doi:10.1093/jjco/hyu112.
   PubMed Web of Science ®Google Scholar
• So KA, Hong JH, Lee JK. Human papillomavirus prevalence and type distribution among 968 women in South Korea. J Cancer Prev. 2016;21(2):104–09. doi:10.15430/JCP.2016.21.2.104.
   PubMedGoogle Scholar
• Chen H-C, You S-L, Hsieh C-Y, Schiffman M, Lin C-Y, Pan M-H, Chou Y-C, Liaw K-L, Hsing AW, Chen C-J, et al. Prevalence of genotype-specific human papillomavirus infection and cervical neoplasia in Taiwan: a community-based survey of 10,602 women. Int J Cancer. 2011;128(5):1192–203. doi:10.1002/ijc.25685.
   PubMed Web of Science ®Google Scholar
• Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J,Bosch FX, de Sanjosé S. ICO/IARC information centre on HPV and cancer (HPV information centre). Human Papillomavirus and Related Diseases in Asia. Summary Report. 2019 [accessed 2020 Jun 30]. http://www.hpvcentre.net/statistics/reports/XSX.pdf .
   Google Scholar
• Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J,Bosch FX, de Sanjosé S. ICO/IARC information centre on HPV and cancer (HPV information centre). Human Papillomavirus and Related Diseases in the World. Summary Report. 2019 [accessed 2020 Jun 30]. http://www.hpvcentre.net/statistics/reports/XWX.pdf.
   Google Scholar
• Roberts C, Green T, Hess E, Matys K, Brown MJ, Haupt RM, Luxembourg A, Vuocolo S, Saah A, Antonello J, et al. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Hum Vaccin Immunother. 2014;10(8):2168–2174. https://www.tandfonline.com/doi/pdf/10.4161/hv.29205?needAccess=true .
   PubMed Web of Science ®Google Scholar
• Stanley M, Pinto LA, Trimble C. Human Papillomavirus Vaccines – immune Responses. Vaccine. 2012;30(Suppl 5):F83–F87. doi:10.1016/j.vaccine.2012.04.106.
   PubMed Web of Science ®Google Scholar
• Garland SM, Pitisuttithum P, Ngan HYS, Cho CH, Lee CY, Chen CA, Yang YC, Chu TY, Twu NF, Samakoses R, et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine: subgroup analysis of participants from Asian countries. J Infect Dis. 2018;218(1):95–108. doi:10.1093/infdis/jiy133.
   PubMed Web of Science ®Google Scholar
• Petersen LK, Restrepo J, Moreira ED Jr., Iversen O-E, Pitisuttithum P, Van Damme P, Joura EA, Olsson S-E, Ferris D, Block S, et al. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials. Papillomavirus Res. 2017;3:105–15. doi:10.1016/j.pvr.2017.03.002.
   PubMed Web of Science ®Google Scholar
• Moreira ED Jr., Block SL, Ferris D, Giuliano AR, Iversen O-E, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, et al. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 Phase III clinical trials. Pediatrics. 2016;138(2):e20154387. doi:10.1542/peds.2015-4387.
   PubMed Web of Science ®Google Scholar